Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Deborah Grayson, a top pharmacist and nutritional therapist, has warned that weight loss medication can cause an inflamed ...

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.